[Source: Market Watch] – NeoPharm, Inc. (other otc:NEOL.PK), a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has completed its merger with Insys Therapeutics, Inc., a Phoenix, AZ based pharmaceutical company.
The combined company creates a near-term commercial organization with a pipeline focused in the pain and oncology space. The company intends to prioritize the combined portfolio of product candidates and focus on taking LEP-ETU into Phase III, while it works towards its NDA submission of the fentanyl sublingual spray. The anticipated filing date is slated for the first quarter of 2011.
For more information: NeoPharm, Inc. Completes Merger with Insys Therapeutics, Inc.